Enliven Therapeutics ELVN Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -26.6%+0.3pp | -27%-1.5pp | -25.4%-0.2pp | -25.3%+6.0pp | -31.3%+0.7pp | |
| Liquidity | ||||||
| Current ratio | 40.3×+11.7× | 28.7×-4.3× | 32.9×+0.4× | 32.6×+11.5× | 21.1×+1.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $7.22-11.0% | $8.11+5.8% | $7.67-18.2% | $9.37+62.8% | $5.76-12.5% | |
| Valuation | ||||||
| Market capitalization | $2.34B+156% | $913.95M-24.6% | $1.21B-2.9% | $1.25B+29.4% | $964.41M-12.3% | |
| Price / book | 5.2×+3.2× | 2×-0.6× | 2.5×0.0× | 2.6×-0.8× | 3.3×-0.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Enliven Therapeutics's ratios come from?
- Every ratio is computed from Enliven Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.